A Study of JR-141 in Patients With Mucopolysaccharidosis II
Study Details
Study Description
Brief Summary
A Phase II/ III multicenter, open-label, single-group, designed to evaluate the efficacy and safety of study drug for the treatment of the MPS II.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2/Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: JR-141 2.0 mg/kg/week
|
Drug: JR-141
IV infusion, 2.0 mg/kg/week
|
Outcome Measures
Primary Outcome Measures
- Change From Baseline in Heparan Sulfate Levels in Cerebrospinal Fluid [Baseline to 52 weeks]
Secondary Outcome Measures
- Change From Baseline in Serum Heparan Sulfate Levels. [Baseline, 24-26 weeks, 50-52 weeks]
- Change From Baseline in Serum Dermatan Sulfate Levels. [Baseline, 24-26 weeks, 50-52 weeks]
- Change From Baseline in Urinary Heparan Sulfate Levels. [Baseline, 25 weeks, 52 weeks]
- Change From Baseline in Urinary Dermatan Sulfate Levels. [Baseline, 25 weeks, 52 weeks]
- Change From Baseline in Liver Volumes. [Baseline, 25 weeks, 52 weeks]
- Change From Baseline in Spleen Volumes. [Baseline, 25 weeks, 52 weeks]
- Change From Baseline in Cardiac Function. [Baseline, 25 weeks, 52 weeks]
- Change From Baseline in 6-minute Walk Test Distance. [Baseline, 25 weeks, 52 weeks]
Item 9 will be administrated only in patients judged by the investigator or subinvestigator to be possible to perform the 6-minutes walk test
- Change From Baseline in Joint Range of Motion. [Baseline, 25 weeks, 52 weeks]
- Change From Baseline in Heparan Sulfate Levels in Cerebrospinal Fluid. [Baseline to 25 weeks]
- Change From Baseline in Dermatan Sulfate Levels in Cerebrospinal Fluid. [Baseline, 25 weeks, 52 weeks]
- Change from Baseline in Neurocognitive Testing (Kyoto Scale of Psychological Development 2001) [25, 52 weeks]
- Change from Baseline in Adaptive Behavioral Testing ( Vineland Adaptive Behavior Scales Second Edition. ) [25, 52 weeks]
- Drug concentration in Cerebrospinal Fluid. [25, 52*weeks]
*Drug concentration in Cerebrospinal Fluid at 52 Weeks is applicable only for subjects to be enrolled in extension study .
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Capable of providing written consent by himself (not mandatory for those aged under 20 years at the time of informed consent process, or those who is impossible to obtain consent from the patient himself due to intellectual disabilities associated with MPS II.)
-
In the case of a patient who is under the age of 20 years or from whom it is not possible to obtain consent due to intellectual disabilities associated with MPS II, he may be included if written consent can be provided by legal representative (however, written consent should be obtained from the patient himself too, whenever possible)
-
Males with confirmed diagnosis of MPS II, based on deficient activity of iduronate-2-sulfatase (IDS) in leucocytes, plasma or fibroblasts and/or pathogenic mutations identified in the IDS gene, etc.
-
Naïve patients or patients who are receiving stable enzyme replacement therapy with Elaprase for more than 8 weeks before the observational period starts.
Exclusion Criteria:
-
Previous engrafted HSCT, excluding those who need enzyme replacement therapy even after HSCT.
-
Judged by the investigator or subinvestigator as being unable to undergo lumbar puncture, including those who have difficulties in taking position for lumbar puncture due to joint contracture or those who are likely experience difficulty breathing during the lumbar puncture process.
-
Judged by the investigator or subinvestigator to be ineligible to participate in the study due to a history of serious drug allergy or sensitivity.
-
Patients who have received other investigational product within 4 months before enrollment in the study.
-
Otherwise judged by the investigator or subinvestigator to be ineligible to participate in the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Fukui Clinical site | Fukui | Japan | 910-1193 | |
| 2 | Fukuoka Clinical site 2 | Fukuoka | Japan | 813-0017 | |
| 3 | Fukuoka Clinical site | Fukuoka | Japan | 830-0011 | |
| 4 | Gifu Clinical site | Gifu | Japan | 501-1194 | |
| 5 | Hokkaido Clinical site | Hokkaido | Japan | 063-0005 | |
| 6 | Kanagawa Clinical site | Kanagawa | Japan | 232-8555 | |
| 7 | Kumamoto Clinical site | Kumamoto | Japan | 860-8556 | |
| 8 | Okayama Clinical site | Okayama | Japan | 701-1192 | |
| 9 | Okayama Clinical site 2 | Okayama | Japan | 710-8602 | |
| 10 | Okinawa Clinical site | Okinawa | Japan | 903-0215 | |
| 11 | Osaka Clinical site 3 | Osaka | Japan | 534-0021 | |
| 12 | Osaka Clinical site 2 | Osaka | Japan | 545-8586 | |
| 13 | Osaka Clinical site | Osaka | Japan | 565-0871 | |
| 14 | Saitama Clinical site | Saitama | Japan | 330-8777 | |
| 15 | Shizuoka Clinical site | Shizuoka | Japan | 420-8660 | |
| 16 | Shizuoka Clinical site 2 | Shizuoka | Japan | 426-8677 | |
| 17 | Tochigi Clinical site | Tochigi | Japan | 329-0498 | |
| 18 | Tokyo Clinical site | Tokyo | Japan | 157-8535 | |
| 19 | Tottori Clinical site | Tottori | Japan | 683-8504 |
Sponsors and Collaborators
- JCR Pharmaceuticals Co., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- JR-141-301